Beijing Kexing Biological Products

Beijing Kexing Biological Products, commonly known as Sinovac, is a leading Chinese biopharmaceutical company specializing in the research, development, and commercialization of vaccines against infectious diseases. The company achieved global prominence with its COVID-19 vaccine, CoronaVac, which is based on an inactivated virus platform and has received emergency use listing from the World Health Organization. Sinovac's commercial portfolio also includes vaccines for Hepatitis A (Healive), Hepatitis B, Enterovirus 71 (Inlive), and seasonal influenza (Anflu). Headquartered in Beijing, the company operates large-scale manufacturing facilities and maintains strategic partnerships for international clinical trials and distribution, particularly in emerging markets. Sinovac continues to advance its pipeline with candidates for pneumococcal diseases, rotavirus, and combination vaccines.